Critical Outcome Technologies Inc. (TSX VENTURE:COT) ("COTI" or the
"Corporation") the bioinformatics and accelerated drug discovery company, is
pleased to announce the completion of a non-brokered private placement of
3,356,250 units (the "Units") at a price of $0.16 per Unit for gross proceeds of
$537,000.


"This financing provides additional funding needed to advance COTI-2 into the
clinic later this year," said John Drake, Chairman of the Board. "Our near term
milestones in this regard include the completion of the final pre-clinical
toxicity studies expected in the second quarter of calendar 2014, and the
preparation of the investigational new drug submission to the U.S. Food and Drug
Administration, which we expect to file in the third quarter. Both of these are
important risk reduction milestones that will further enhance the attractiveness
of COTI-2 for licensing." 


Each Unit consists of one common share and one warrant of the Corporation. Each
warrant is exercisable for one common share of the Corporation at an exercise
price of $0.28 per share for a period of 24 months from the date of issue. 


The common shares and warrants comprising the Units, as well as the common
shares issuable upon the exercise of the warrants, are subject to restrictions
on resale which expire on September 1, 2014 in accordance with applicable
securities laws and the policies of the TSX Venture Exchange. The offering is
subject to final acceptance by the TSX Venture Exchange.


About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI's proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Notice to Readers

Information contained in this press release may contain certain statements,
which constitute "forward- looking statements" within the meaning of the
Securities Act (Ontario) and applicable securities laws. For example, the
statement, "... to advance COTI-2 into the clinic later this year " and "... the
final pre-clinical toxicity studies expected in the second quarter of calendar
2014, and the preparation of the investigational new drug submission to the U.S.
Food and Drug Administration, which we expect to file in the third quarter" are
forward-looking statements. Forward-looking statements by their nature are not
guarantees of future performance and are based upon management's current
expectations, estimates, projections, and assumptions. COTI operates in a highly
competitive environment that involves significant risks and uncertainties, which
could cause actual results to differ materially from those anticipated in these
forward-looking statements. Management of COTI considers the assumptions on
which these forward-looking statements are based to be reasonable, but as a
result of the many risk factors, cautions the reader that actual results could
differ materially from those expressed or implied in these forward-looking
statements. Information in this press release should be considered accurate only
as of the date of the release and may be superseded by more recent information
disclosed in later press releases, filings with the securities regulatory
authorities or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com
Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Cotinga Pharmaceuticals Charts.
Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Cotinga Pharmaceuticals Charts.